Insider · CIK 0001114914
Jon S Saxe
Files at VTGN (Vistagen Therapeutics, Inc.). First filing -, latest -.
Jon S Saxe files SEC Form 4 as director at VTGN (Vistagen Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jon S Saxe has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2025 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Sep 11, 2025 |
Questions about Jon S Saxe
Answered from the filings on this page, as of the latest one.
Is Jon S Saxe buying or selling?
Jon S Saxe has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jon S Saxe's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jon S Saxe has 0.
Where does Jon S Saxe file Form 4?
Jon S Saxe has filed Form 4 at VTGN (Vistagen Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.